Form 4 Filing for Monte Rosa Therapeutics, Inc.

Sharon Townson, Chief Scientific Officer of Monte Rosa Therapeutics, Inc., executed a series of transactions on July 6, 2026, under a Rule 10b5-1 trading plan. Townson acquired 6,000 shares of Common Stock at a price of $6.14 per share. Subsequently, she disposed of 5,600 shares at a weighted average price of $23.2495 (ranging from $22.97 to $23.65) and an additional 400 shares at $24.13 per share. Concurrently, Townson exercised a stock option (right to buy) for 6,000 shares of Common Stock at an exercise price of $6.14 per share. These transactions were reported on a Form 4 filing, with the signature date of July 7, 2026.